Cancer Treatment
Researchers from the United States publish new studies and findings in the area of cancer treatment
Published in Gene Therapy Weekly, November 9th, 2006
Study 1: Recent research from the United States published in the journal Leukemia Research has chronicled a phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine (HiDAC) during induction.
"Randomized trials of substituting HiDAC for standard dose cytarabine (SDAC) during induction therapy for newly diagnosed AML have not demonstrated an improvement in the complete remission (CR) rate. Phase II trials...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-11-09)
More Articles from Gene Therapy Weekly
- Cholangiocarcinoma
Cholangiocarcinoma cell growth inhibited by receptor ligand - Genetics & Genomics
MicroRNA expression detected by RNA oligonucleotide hybridization - Genetics & Genomics
Therapeutic exon skipping achieved in Duchenne muscular dystrophy - RNA Interference
RNA interference-mediated enzyme silencing achieves therapeutic benefit - Vector Development
Lentiviral vector may be used to study and treat proliferative diseases - Cancer Gene Therapy
Reports outline cancer gene therapy research from West Virginia University, Mary Babb Randolph Cancer Center - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
